Literature DB >> 1303684

Autoantibodies to the Ro/SSA autoantigen are conformation dependent. II: Antibodies to the denatured form of 52 kD Ro/SSA are a cross reacting subset of antibodies to the native 60 kD Ro/SSA molecule.

Y Itoh1, K Itoh, M B Frank, M Reichlin.   

Abstract

The immune response to the Ro/SSA particles is conformation dependent. In sera with only anti-Ro/SSA precipitins, the autoantibodies to the 60 kD Ro/SSA are largely to the native 60 kD Ro/SSA while autoantibodies to the 52 kD Ro/SSA particle when present are exclusively to the denatured 52 kD Ro/SSA particle. Antibodies eluted from a recombinant 52 kD Ro/SSA fusion protein reacted in a sandwich ELISA which only measures antibody to native 60 kD Ro/SSA antigens and this reaction is largely inhibited by native homogeneous 60 kD Ro/SSA. In addition, antibody binding to the 52 kD Ro/SSA antigen in Western blot is also strongly inhibited by native 60 kD Ro/SSA. These experiment strongly suggest that reactivity of denatured 52 kD Ro/SSA antigen represents a cross reaction with autoantibodies directed to the native 60 kD Ro/SSA antigen. As a corollary of these experiments, data are presented that suggest the hY-RNAs are not associated with the 52 kD Ro/SSA protein but only with the 60 kD Ro/SSA protein. These data are consistent with the hypothesis that the autoanti-Ro/SSA response is driven by native 60 kD Ro/SSA and the immune response to denatured 52 kD Ro/SSA is largely a cross-reactive subset of the immune response to native 60 kD Ro/SSA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303684     DOI: 10.3109/08916939209083125

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  12 in total

1.  Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation?

Authors:  R J Lock; D J Unsworth
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

Review 2.  Autoantibodies to the RoRNP particles.

Authors:  M Reichlin
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

3.  Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins.

Authors:  A Kelekar; M R Saitta; J D Keene
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

4.  Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein.

Authors:  G Boire; M Gendron; N Monast; B Bastin; H A Ménard
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 5.  Neonatal lupus: clinical features, therapy, and pathogenesis.

Authors:  L A Lee
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

6.  Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen.

Authors:  B T Kurien; J Newland; C Paczkowski; K L Moore; R H Scofield
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  Expression and DNA binding of the human 52 kDa Ro/SSA autoantigen.

Authors:  M B Frank; V R McCubbin; C Heldermon
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

8.  Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera.

Authors:  V Ricchiuti; J P Briand; O Meyer; D A Isenberg; G Pruijn; S Muller
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

9.  Immunogenetics of epitopes of the carboxyl terminus of the human 60-kD Ro autoantigen.

Authors:  R H Scofield; W D Dickey; K L Hardgrave; B R Neas; R M Horowitz; R A McArthur; A Fujisaku; M B Frank; J B Harley; A ] Fujisak A [corrected to Fujisaku
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

Review 10.  Clinical and pathological roles of Ro/SSA autoantibody system.

Authors:  Ryusuke Yoshimi; Atsuhisa Ueda; Keiko Ozato; Yoshiaki Ishigatsubo
Journal:  Clin Dev Immunol       Date:  2012-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.